0001171843-26-001561
SEC filingXBiotech Inc. reported a net loss of $45.5 million for fiscal year 2025, compared to a net loss of $38.5 million in 2024. The company generated no revenue during the period, consistent with its pre-market biopharmaceutical status. Total operating expenses increased to $55.7 million from $42.5 million in the prior year, driven primarily by a 26% increase in research and development expenses to $47.4 million, which included $17.3 million in severance and a $4.5 million bonus paid to former CEO John Simard upon his retirement. The company ended the year with $125.6 million in cash and cash equivalents, down from $172.7 million at the end of 2024, with management stating this provides sufficient resources to fund operations for at least the next 12 months. The company continues to advance its True Human™ monoclonal antibody pipeline, including Natrunix for oncology and Hutrukin for stroke, but faces significant regulatory and clinical development risks.
XBiotech Inc. reported deteriorating financial results for fiscal year 2025, with net loss increasing to $45.5 million from $38.5 million in 2024. The company generated no revenue during either period, consistent with its status as a pre-market biopharmaceutical company. Total operating expenses rose significantly to $55.7 million from $42.5 million in the prior year, representing a 31.1% increase. The loss from operations widened to $55.7 million from $42.5 million in 2024. Other income provided some offset at $10.4 million, primarily from interest income of $5.7 million and foreign exchange gains of $3.3 million. The company's accumulated deficit grew to $136.4 million at December 31, 2025, from $90.8 million at the end of 2024.
The company generated no revenue during fiscal year 2025, consistent with its pre-market status and lack of commercial products. The document explicitly states: "During the fiscal year of 2026, we don't expect to generate any revenue" and "To date, we have not generated any revenue from commercial product sales." The company's ability to generate future revenue depends entirely on successful development and regulatory approval of its product candidates. The company previously received $750 million from the sale of Bermekimab to Janssen in 2019, but this was characterized as an extraordinary transaction outside normal business operations. The company may be eligible for up to $600 million in milestone payments from Janssen, but these are contingent on Janssen's business decisions and regulatory approvals.
As a pre-revenue company, traditional margin analysis is not applicable. The company's operating loss margin (loss from operations as a percentage of total assets) was 37.1% in 2025, compared to 21.3% in 2024, reflecting increased spending without corresponding revenue. Research and development expenses constituted 85% of total operating expenses in 2025, up from 89% in 2024, while general and administrative expenses represented 15% of operating expenses, up from 11% in the prior year. The increase in R&D expenses was primarily driven by $17.3 million in severance and a $4.5 million bonus paid to former CEO John Simard upon his retirement in December 2025. Share-based compensation expense increased to $3.6 million from $1.8 million in 2024.
The company's cash position declined to $125.6 million at December 31, 2025, from $172.7 million at the end of 2024. Net cash used in operating activities was $39.9 million in 2025, compared to $31.0 million in 2024. The company used $0.3 million in investing activities for property and equipment purchases and repaid $10.3 million in financing activities related to convertible loans. Total assets decreased to $150.1 million from $199.1 million year-over-year, while total liabilities declined to $9.7 million from $16.8 million. Shareholders' equity stood at $140.3 million, down from $182.3 million in 2024. Management stated that current cash resources are sufficient to fund operations for at least the next 12 months.
The company expects to continue incurring significant operating losses for the foreseeable future as it advances its drug candidates through development. Management stated: "We will need to generate significant revenues to achieve or sustain profitability, and we may never do so." The company faces numerous risks including clinical trial failures, regulatory approval uncertainties, competition, and dependence on key personnel. Specific pipeline developments include Natrunix for oncology (completed Phase II study in pancreatic cancer) and Hutrukin for stroke (completed Phase I study), but regulatory paths remain uncertain. The company also has infectious disease candidates in development. Management noted that general and administrative costs are expected to increase due to inflationary trends. The company's ability to continue operations depends on successful development of its pipeline or obtaining additional financing.